Barry Trachtenberg

Barry Trachtenberg


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
BTBarry Trachtenberg
Barry Trachtenberg
ACAndrea M. Cordero-Reyes
Andrea M. Cordero-Reyes
MAMolham Aldeiri
Molham Aldeiri
PAPaulino A. Alvarez
Paulino A. Alvarez
ABArvind Bhimaraj
Arvind Bhimaraj
JEJerry D. Estep
Jerry D. Estep

31 January 2021 in Cardio-Oncology
Verified
Journal Article
Open access
PDF file
RARaquel Araujo-Gutierrez
Raquel Araujo-Gutierrez
KCKalyan R. Chitturi
Kalyan R. Chitturi
JXJiaqiong Xu
Jiaqiong Xu
YWYuanchen Wang
Yuanchen Wang
EKElizabeth Kinder
Elizabeth Kinder
BTBarry Trachtenberg
Barry Trachtenberg
Background: Cancer therapy-related cardiac dysfunction (CTRD) is a major source of morbidity and mortality in long-term cancer survivors. Decreased GLS predicts decreased left ventricular ejection fraction (LVEF) in patients receiving anthracyclines, but knowledge regarding the clinical utility of baseline GLS in patients at low-risk of (CTRD) is limited. Objectives: The purpose of this study was to investigate whether baseline echocardiographic assessment of global longitudinal strain (GLS) before treatment with anthracyclines is predictive of (CTRD) in a broad cohort of patients with normal baseline LVEF. Methods: Study participants comprised 188 patients at a single institution who underwent baseline 2-dimensional (2D) speckle-tracking echocardiography before treatment with anthracyclines and at least one follow-up echocardiogram 3 months after chemotherapy initiation. Patients with a baseline LVEF 10% from baseline and an overall reduced LVEF <50%. Potential and known risk factors were evaluated using univariable and multivariable Cox proportional hazards regression analysis. Results: Twenty-three patients (12.23%) developed (CTRD). Among patients with (CTRD), the mean GLS was -17.51% ± 2.77%. The optimal cutoff point for (CTRD) was -18.05%. The sensitivity was 0.70 and specificity was 0.70. The area under ROC curve was 0.70. After adjustment for cardiovascular and cancer therapy related risk factors, GLS or decreased baseline GLS ≥-18% was predictive of (CTRD) (adjusted hazards ratio 1.17, 95% confidence interval 1.00, 1.36; p = 0.044 for GLS, or hazards ratio 3.54; 95% confidence interval 1.34, 9.35; p = 0.011 for decreased GLS), along with history of tobacco use, pre-chemotherapy systolic blood pressure, and cumulative anthracycline dose. Conclusions: Baseline GLS or decreased baseline GLS was predictive of (CTRD) before anthracycline treatment in a cohort of cancer patients with a normal baseline LVEF. This data supports the implementation of strain-protocol echocardiography in cardio-oncology practice for identifying and monitoring patients who are at elevated risk of (CTRD).

23 December 2022 in Science Advances
Verified
Journal Article
Open access
JLJing Liu
Jing Liu
SLSarah Lane
Sarah Lane
RLRahul Lall
Rahul Lall
MRMichele Russo
Michele Russo
LFLaurie Farrell
Laurie Farrell
AAAarti Asnani
Aarti Asnani
Anthracyclines such as doxorubicin (Dox) are effective chemotherapies, but their use is limited by cardiac toxicity. We hypothesized that plasma proteomics in women with breast cancer could identify new mechanisms of anthracycline cardiac toxicity. We measured changes in 1317 proteins in anthracycline-treated patients ( n = 30) and replicated key findings in a second cohort ( n = 31). An increase in the heme-binding protein hemopexin (Hpx) 3 months after anthracycline initiation was associated with cardiac toxicity by echocardiography. To assess the functional role of Hpx, we administered Hpx to wild-type (WT) mice treated with Dox and observed improved cardiac function. Conversely, Hpx −/− mice demonstrated increased Dox cardiac toxicity compared to WT mice. Initial mechanistic studies indicate that Hpx is likely transported to the heart by circulating monocytes/macrophages and that Hpx may mitigate Dox-induced ferroptosis to confer cardioprotection. Together, these observations suggest that Hpx induction represents a compensatory response during Dox treatment.

22 February 2023 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
BTBarry Trachtenberg
Barry Trachtenberg
JCJennifer Cowger
Jennifer Cowger
DJDouglas L. Jennings
Douglas L. Jennings
GGGillian Grafton
Gillian Grafton
RLRenzo Loyaga-Rendon
Renzo Loyaga-Rendon
EVEsther Vorovich
Esther Vorovich

17 March 2021 in Diseases
Verified
Journal Article
Open access
PDF file
EBEthan Burns
Ethan Burns
CGCesar Gentille
Cesar Gentille
BTBarry Trachtenberg
Barry Trachtenberg
SPSai Ravi Pingali
Sai Ravi Pingali
Kartik AnandKartik Anand
Kartik Anand
Chimeric antigen receptor T-cells (CAR-T) are improving outcomes in pediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemias and subtypes of non-Hodgkin Lymphoma. As this treatment is being increasingly utilized, a better understanding of the unique toxicities associated with this therapy is warranted. While there is growing knowledge on the diagnosis and treatment of cytokine release syndrome (CRS), relatively little is known about the associated cardiac events that occur with CRS that may result in prolonged length of hospital stay, admission to the intensive care unit for pressor support, or cardiac death. This review focuses on the various manifestations of cardiotoxicity, potential risk factors, real world and clinical trial data on prevalence of reported cardiotoxicity events, and treatment recommendations.

1 June 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
BTBarry Trachtenberg
Barry Trachtenberg
RKRammurti T. Kamble
Rammurti T. Kamble
LRLawrence Rice
Lawrence Rice
RARaquel Araujo-Gutierrez
Raquel Araujo-Gutierrez
ABArvind Bhimaraj
Arvind Bhimaraj
JEJerry D. Estep
Jerry D. Estep
This study sought to retrospectively investigate the outcomes of patients with light‐chain amyloidosis (AL) with advanced cardiac involvement who were treated with a strategy of heart transplantation (HT) followed by delayed autologous stem cell transplantation (ASCT) at one‐year post‐transplant. Patients with AL amyloidosis with substantial cardiac involvement have traditionally had very poor survival (e.g. several months). A few select centers have reported their outcomes for HT followed by a strategy of early ASCT (i.e. 6 months) for CA. The outcomes of patients undergoing a delayed strategy has not been reported. All patients with AL amyloidosis at a single institution undergoing evaluation for HT from 2004‐2018 were included. Retrospective analyses were performed. Sixteen patients underwent HT (including two combined heart‐kidney transplant) for AL amyloidosis. ASCT was performed in a total of 9 patients to date at a median 13.5 months (12.8‐32.9 months) post‐HT. Survival was 87.5% at 1‐year and 76.6% at 5 years, comparable to institutional outcomes for non‐amyloid HT recipients. A strategy of delayed ASCT one‐year post‐HT for patients with AL amyloidosis is feasible, safe, and associated with comparable outcomes to those undergoing an earlier ASCT strategy.